Efficacy and safety analysis of denosumab in the treatment of osteoporosis in elder female patients with type 2 diabetes mellitus
10.3969/j.issn.1006-6187.2025.06.008
- VernacularTitle:地舒单抗治疗老年女性2型糖尿病合并骨质疏松症患者的疗效和安全性分析
- Author:
Huanjun WANG
1
;
Lin LI
;
Li HU
;
Xuanyu DENG
;
Guangpeng RUAN
;
Yinzhen PI
Author Information
1. 410005 中南大学湘雅医学院附属长沙医院内分泌代谢科
- Publication Type:Journal Article
- Keywords:
Diabetes mellitus,type 2;
Denosumab;
Bone mineral density;
Osteoporosis
- From:
Chinese Journal of Diabetes
2025;33(6):439-443
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the efficacy and safety of denosumab(DEN)in the treatment of type 2 diabetes mellius(T2DM)complicated with osteoporosis(OP).Methods The DEN's efficacy on bone metabolism and glucose metabolism in patients with T2DM and OP was retrospectively analyzed through a before-and-after self-controlled design.Forty-one T2DM patients combined with OP who were treated in The First Hospital of Changsha from January 2022 to December 2022 were selected.All patients were observed with subcutaneous injection of DEN 60 mg every 6 months for 12 months.The changes of HbA1c,FPG,bone metabolism indexes,25-hydroxyvitamin D[25(OH)D]and bone mineral density(BMD)of patients before and after DEN treatment were compared.The adverse reactions of DEN were recorded.Results After 12 months of treatment,25(OH)D,the BMD oflumbar vertebra(L1～4),left femoral neck and left hip were higher than before treatment(P<0.05),while the osteocalcin,β-collagen special series,parathyroid hormone and alkaline phosphatase were lower than before treatment(P<0.05),and the adverse reactions were reduced.Conclusions DEN can significantly improve bone metabolism in patients with T2DM and osteoporosis,increase BMD of lumbar spine and whole hip with fewer adverse reactions.
